Picture [iito] No Tracking 650x80px
Document › Details

CRISPR Therapeutics AG. (10/28/19). "Press Release: CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2019 Financial Results". Zug & Cambridge, MA.

Organisations Organisation CRISPR Therapeutics AG (Nasdaq: CRSP)
  Group CRISPR Therapeutics (Group)
  Organisation 2 ViaCyte Inc.
  Group ViaCyte (Group)
Products Product CTX001 (CRISPR Therapeutics/Vertex)
  Product 2 CTX110 allogeneic CAR-T cell therapy
Index terms Index term Vertex–CRISPR Therapeutics: CRISPR technology, 201510– collab research $75m upfront + $30m investm + milestones + royalties to treat genetic diseases
  Index term 2 Bayer–CRISPR Therapeutics: CRISPR technology, 201512–201910 collab 50/50 joint venture w minimum of $300m r+d investment by Bayer in next 5 years
Persons Person Kulkarni, Samarth (Sam) (CRISPR Therapeutics 201712– promoted CEO before CBO)
  Person 2 Kim, Susan (CRISPR Therapeutics 201809 Investor Relations)

Record changed: 2019-11-03


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for CRISPR Therapeutics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

» top